{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=113", "query": { "intervention": "serum sample", "page": 113 }, "page_size": 10 }, "pagination": { "page": 113, "page_size": 10, "total_count": 8383, "total_pages": 839, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=114&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=112&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T22:29:11.532Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00520572", "title": "A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "AZD9056", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2007-08", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 8, "location_summary": "Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Petoskey", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00520572" }, { "nct_id": "NCT01090323", "title": "Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "ICL670", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 185, "start_date": "2004-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2011-06-06", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 31, "location_summary": "Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01090323" }, { "nct_id": "NCT02152696", "title": "Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Persistent Pregnancy of Unknown Location", "Ectopic Pregnancy" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Uterine Evacuation", "type": "PROCEDURE" }, { "name": "Expectant Management", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 255, "start_date": "2014-07-25", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 17, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152696" }, { "nct_id": "NCT00060346", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2004-10-05", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 153, "location_summary": "Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060346" }, { "nct_id": "NCT02117362", "title": "Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "1 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "2 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "4 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "8 mg/kg GR-MD-02", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-05-08", "completion_date": "2018-11-28", "has_results": false, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02117362" }, { "nct_id": "NCT05062317", "title": "ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Metastases" ], "interventions": [ { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FLUOROURACIL", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-04-26", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05062317" }, { "nct_id": "NCT03222076", "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Resectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-09-28", "completion_date": "2022-09-14", "has_results": true, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222076" }, { "nct_id": "NCT07562997", "title": "Sodium and Milk Fortification Evaluation of Body Composition Among Very Preterm Infants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Very Preterm and Extremely Preterm Birth" ], "interventions": [ { "name": "Urine sodium testing", "type": "DIAGNOSTIC_TEST" }, { "name": "Serum sodium testing", "type": "DIAGNOSTIC_TEST" }, { "name": "Milk fortification", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "14 Days", "sex": "ALL", "summary": "0 Days to 14 Days" }, "enrollment_count": 150, "start_date": "2026-05-18", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 3, "location_summary": "Cincinnati, Ohio • Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07562997" }, { "nct_id": "NCT04179110", "title": "Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transitional Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab and Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-09-18", "completion_date": "2023-06-15", "has_results": false, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179110" }, { "nct_id": "NCT01285323", "title": "A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Asthma" ], "interventions": [ { "name": "Reslizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 464, "start_date": "2011-03", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-11-08T22:29:11.532Z", "location_count": 15, "location_summary": "Mobile, Alabama • Fresno, California • Long Beach, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Waterbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285323" } ] }